Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency—Centromeric Instability—Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-024-01786-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Dagmar Berghuis und 17 weiteren Autor:innen. Beteiligte Einrichtung: Willem-Alexander Children's Hospital, Department of Pediatrics, Division of Pediatric Immunology, Hematology and Stem Cell Transplantation, Leiden Un…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Transplantation, Homologous, Graft vs Host Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunodeficiency–Centromeric instability–Facial dysmorphism (ICF) syndrome is an inborn error of immunity characterized by progressive immune dysfunction and multi-organ disease usually treated with antimicrobial prophylaxis and immunoglobulin substitution. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment, but data on outcome are scarce. We provide a detailed description of disease characteristics and HSCT outcome in an international cohort of ICF syndrome patients. Eighteen patients (including all four genotypes) were enrolled. Main HSCT indications were infections (83%), enteropathy/failure to thrive (56%), immune dysregulation (22%) and myelodysplasia/haematological malignancy (17%). Two patients underwent pre-emptive HSCT after early diagnosis. Patients were transplanted between 2003–2021, at median age 4.3 years (range 0.5–19), after myeloablative or reduced-intensity conditioning, from matched sibling or matched family donors, matched unrelated or mismatched donors in 39%, 50% and 12% of cases respectively. Overall survival was 83% (all deaths occurred within the first 5 months post-HSCT; mean follow-up 54 months (range 1–185)). Acute GvHD occurred in 35% of patients, severe (grade III) in two (12%), while none developed chronic GvHD. At latest follow-up (median 2.2 years (range 0.1–14)), complete donor chimerism was achieved in 15/17 surviving patients. All survivors demonstrated normalized T and B cell numbers. Immunoglobulin substitution independence was achieved in all but two patients. All survivors recovered from pre-transplant infections, enteropathy/failure to thrive and immune dysregulation. All three patients transplanted at young age (≤ 3 years), after early diagnosis, survived. The favourable clinical and immunological HSCT outcome in this cohort of patients supports the timely use of this curative treatment in ICF syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Willem-Alexander Children's Hospital, Department of Pediatrics, Division of Pediatric Immunology, Hematology and Stem Cell Transplantation, Leiden University Medical Center, Leiden, The Netherlands. d.berghuis@lumc.nl.
- Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Dayton Children's Hospital/Department of Pediatrics, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.
- The Blood and Marrow Transplant Program, Nationwide Children's Hospital, Colombia, OH, USA.
- Department of Pediatrics, Dr. Von Hauner Children's Hospital, University Hospital, LMU, Munich, Germany.
- Division of Blood and Marrow Transplantation and Cellular Therapies, University of Pittsburgh Medical Center (UPMC) and Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, University Hospital…
ORCID-Profile: Dagmar Berghuis, Lubna S Mehyar, Michael H Albert, Horst von Bernuth, Alexandra Laberko, Corry M R Weemaes, Akif Yesilipek, Arjan C Lankester
Zitieren
APA
Berghuis, D., Mehyar, L. S., Abu-Arja, R., Albert, M. H., Barnum, J. L., von Bernuth, H., Elfeky, R., Lewalle, P., Laberko, A., Ghosh, S., Slatter, M. A., Weemaes, C. M. R., Yesilipek, A., Sirait, T., Neven, B., Gennery, A. R., Lankester, A. C., & Inborn Errors Working Party (IEWP) of the European Society for Immunodeficiencies (ESID), the European Society for Blood and Marrow Transplantation (EBMT) and… (2024). Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency—Centromeric Instability—Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01786-7
Vancouver
Berghuis D, Mehyar LS, Abu-Arja R, Albert MH, Barnum JL, von Bernuth H, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency—Centromeric Instability—Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01786-7
BibTeX
@article{Berghuis2024,
author = {Berghuis, Dagmar and Mehyar, Lubna S and Abu-Arja, Rolla and Albert, Michael H and Barnum, Jessie L and von Bernuth, Horst and Elfeky, Reem and Lewalle, Philippe and Laberko, Alexandra and Ghosh, Sujal and Slatter, Mary A and Weemaes, Corry M R and Yesilipek, Akif and Sirait, Tiarlan and Neven, Bénédicte and Gennery, Andrew R and Lankester, Arjan C and Inborn Errors Working Party (IEWP) of the European Society for Immunodeficiencies (ESID), the European Society for Blood and Marrow Transplantation (EBMT) and…, Inborn Errors Working Party (IEWP) of the European Society for Immunodeficiencies (ESID), the European Society for Blood and Marrow Transplantation (EBMT) and…},
title = {Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency—Centromeric Instability—Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-024-01786-7}
}
EUVIMED